Ascendis Pharma A/S (BVMF:A1SN34)
89.46
0.00 (0.00%)
At close: Jun 26, 2026
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 246.60M EUR in the quarter ending March 31, 2026, with 144.27% growth. This brings the company's revenue in the last twelve months to 865.78M, up 134.82% year-over-year. In the year 2025, Ascendis Pharma had annual revenue of 720.13M with 98.03% growth.
Revenue (ttm)
865.78M EUR
Revenue Growth
+134.82%
P/S Ratio
16.31
Revenue / Employee
728.16K EUR
Employees
1,189
Market Cap
84.96B BRL
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 720.13M | 356.49M | 98.03% |
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Dec 31, 2022 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | 13.38M | 2.79M | 26.41% |
| Dec 31, 2018 | 10.58M | 9.05M | 591.57% |
| Dec 31, 2017 | 1.53M | -3.08M | -66.78% |
| Dec 31, 2016 | 4.61M | -3.51M | -43.26% |
| Dec 31, 2015 | 8.12M | -5.87M | -41.94% |
| Dec 31, 2014 | 13.98M | -6.43M | -31.48% |
| Dec 31, 2013 | 20.41M | 4.83M | 30.96% |
| Dec 31, 2012 | 15.58M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rede D'Or São Luiz | 57.09B |
| Raia Drogasil | 45.55B |
| Empreendimentos Pague Menos | 15.34B |
| Diagnósticos da América | 9.57B |
| Hypera | 8.64B |
| Fleury | 8.50B |
| Dimed S.A. Distribuidora de Medicamentos | 5.70B |
| Bradsaúde | 2.57B |
Ascendis Pharma News
- 3 days ago - Ascendis Pharma added to multiple Russell U.S. Indexes - TheFly
- 3 days ago - Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap® - GlobeNewsWire
- 4 days ago - Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 - GlobeNewsWire
- 15 days ago - Ascendis Pharma completes Phase 3 PaTHway Trial - TheFly
- 16 days ago - Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism - GlobeNewsWire
- 18 days ago - Ascendis Pharma announces five-year data from PaTH Forward Trial - TheFly
- 18 days ago - 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism - GlobeNewsWire
- 21 days ago - Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer - TheFly